KTTA

Pasithea Therapeutics Corp. (KTTA) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders and RASopathies. The company's lead candidate, PAS-004 (a MEK inhibitor), is currently in a Phase 1 dose escalation study. The company is classified as a Smaller Reporting Company and an Emerging Growth Company.

Key Financial Metrics

Debt and Liabilities: Total liabilities were $1,680,199. Current liabilities include $268,969 in financed director and officer insurance premiums. There are no long-term debt obligations other than warrant liabilities ($85,305).

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $298,000 (7.7%) compared to Q1 2024, driven primarily by reduced General and Administrative (G&A) expenses.
• Expense Management: G&A expenses decreased by $341,000 (14.9%) due to lower legal fees, stock-based compensation, and public company costs. Research and Development (R&D) expenses remained relatively flat, decreasing only $19,000 (1.1%), as reductions in preclinical costs were offset by increased clinical trial expenses for the PAS-004 Phase 1 study.
• Cash Position: Cash and cash equivalents declined by $1.6 million during the quarter, a significant improvement in burn rate compared to the $4.3 million decline in Q1 2024.
• Capital Raising: The company raised approximately $1.65 million in net proceeds from At-The-Market (ATM) stock sales and exercised pre-funded warrants for $871 in proceeds during the quarter.

Outlook, Risks, and Subsequent Events

Liquidity and Going Concern: Management explicitly states there is substantial doubt about the company's ability to continue as a going concern for twelve months from the filing date without additional funding. As of March 31, 2025, cash reserves of $5.3 million are insufficient to meet operational needs through the next year.

Clinical Progress:

• Completed enrollment and initial dosing of Cohort 6 in the PAS-004 Phase 1 study (April 2025).
• Announced pharmacodynamics results showing robust target engagement (May 2025).
• Initiated Phase 1/1b clinical trial for PAS-004 in adult patients with NF1-associated neurofibromas (May 2025).

Subsequent Events (Post-March 31, 2025):

• May 2025 Public Offering: Closed an offering of 3.57 million shares (or pre-funded warrants) and accompanying warrants at $1.40 per unit. Total gross proceeds were approximately $6.3 million (including $1.3 million from warrant exercises).
• ATM Sales: Sold an additional 252,600 shares under the ATM agreement for net proceeds of $358,037.

Risks: The company faces significant risks related to its lack of operating history, dependence on capital markets, and the uncertainty of clinical trial outcomes. Inflationary pressures are also noted as a factor increasing operational costs.

Investor Verification Checklist

• Cash Runway: Verify the impact of the May 2025 offering ($6.3M gross) on the company's liquidity runway and whether it resolves the "going concern" uncertainty.
• Dilution: Assess the dilution impact from the May 2025 offering and the outstanding warrant pool (approx. 3.3 million warrants outstanding as of March 31).
• Clinical Milestones: Monitor the safety and efficacy data from the PAS-004 Phase 1/1b trial in NF1 patients initiated in May 2025.
• Expense Trends: Confirm if the reduction in G&A expenses is sustainable or if one-time cost cuts were made.
• Warrant Liability: Track the fair value of warrant liabilities, which fluctuate with stock price and can impact net income/loss.